$1.99
+0.09 (+4.74%)
Open$1.92
Previous Close$1.90
Day High$2.04
Day Low$1.92
52W High$3.54
52W Low$0.66
Volume—
Avg Volume1.00M
Market Cap184.58M
P/E Ratio—
EPS$-1.59
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+306.0% upside
Current
$1.99
$1.99
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.39M | 13.32M | 54.83M |
| Net Income | -164,470,603 | -159,079,573 | 10.00M |
| Profit Margin | -1,327.4% | -1,261.0% | 18.2% |
| EBITDA | -161,038,300 | -164,413,095 | 16.80M |
| Free Cash Flow | — | — | 9.93M |
| Rev Growth | -7.0% | -7.0% | -2.4% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |